lenalidomide has been researched along with Dermatoses in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nguyen, BD | 1 |
| Ahlberg, L; Alici, E; Blimark, C; Carlsson, C; Forsberg, K; Gréen, H; Gruber, A; Hardling, M; Jakobsen Falk, I; Lauri, B; Lotfi, K; Lund, J; Mellqvist, UH; Nahi, H; Swedin, A | 1 |
| Ando, K; André, M; Bartlett, NL; Bouabdallah, K; Bouabdallah, R; Brice, P; Cartron, G; Casasnovas, RO; Daguindau, N; Feugier, P; Flinn, IW; Fowler, NH; Fruchart, C; Gomes da Silva, M; Haioun, C; Larouche, JF; Le Gouill, S; Libby, EN; Liu, D; López-Guillermo, A; Maisonneuve, H; Martin Garcia-Sancho, A; Morschhauser, F; Palomba, ML; Pica, GM; Ribrag, V; Salles, GA; Sehn, LH; Tilly, H; Tobinai, K; Wang, J; Xerri, L; Ysebaert, L; Zachée, P | 1 |
| Descamps, V | 1 |
| Cosiglio, FJ; Ordi-Ros, J | 1 |
| Nahmias, Z; Nambudiri, VE; Vleugels, RA | 1 |
2 review(s) available for lenalidomide and Dermatoses
| Article | Year |
|---|---|
[What's new in dermatological treatment?]
Topics: Antibodies, Monoclonal; Capecitabine; Clinical Trials as Topic; Dermatologic Agents; Dermatology; ErbB Receptors; Humans; Immunologic Factors; Interleukins; Lenalidomide; Receptor, Anaphylatoxin C5a; Receptors, Interleukin; Skin Diseases; Tranexamic Acid; Tumor Necrosis Factor-alpha | 2018 |
[Current therapeutic indications of thalidomide and lenalidomide].
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; Endocrine System Diseases; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Humans; Immunologic Factors; Inflammation; Lenalidomide; Neoplasms; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Safety-Based Drug Withdrawals; Skin Diseases; Thalidomide; Thrombophilia; Vasculitis | 2014 |
2 trial(s) available for lenalidomide and Dermatoses
| Article | Year |
|---|---|
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Prospective Studies; Skin Diseases; Treatment Outcome | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Neutropenia; Rituximab; Skin Diseases; Survival Rate; Thalidomide | 2018 |
2 other study(ies) available for lenalidomide and Dermatoses
| Article | Year |
|---|---|
Hepatobiliary and Pancreatic: Hepatic necrobiotic xanthogranuloma.
Topics: Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Liver; Liver Diseases; Magnetic Resonance Imaging; Middle Aged; Necrobiotic Xanthogranuloma; Positron Emission Tomography Computed Tomography; Skin; Skin Diseases | 2017 |
Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions.
Topics: Adult; Aged; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Retreatment; Skin Diseases; Thalidomide | 2016 |